Rac1: A potential radiosensitization target of human nasopharyngeal carcinoma CNE2 cells.


Journal

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982

Informations de publication

Date de publication:
01 Aug 2020
Historique:
received: 11 11 2019
revised: 05 05 2020
accepted: 11 05 2020
pubmed: 27 5 2020
medline: 22 6 2021
entrez: 27 5 2020
Statut: ppublish

Résumé

Radiotherapy has a high cure rate for early nasopharyngeal carcinoma(NPC). However, the radiation resistance of poorly differentiated NPC cells impacts the effectiveness of treatment of early-stage NPC patients. Here, we explored the relationship between Ras-related C3 botulinum toxin substrate 1(Rac1) expression and NPC radiosensitivity. In vitro and in vivo studies revealed that upregulation of Rac1, when combined with X-ray treatment, increased growth inhibition and induced remarkable morphological changes and apoptosis in CNE2 cells. Furthermore, rupturing of the cell and nuclear membranes, degeneration of the cristae and significant swelling of the mitochondria were observed, which were consistent with the high apoptotic rate. The Rac1(+) cells exhibited approximately 50% more migration compared with that of the NC and Rac1(-) cells. The overexpression of Rac1 can increase the radiation sensitivity of NPC CNE2 cells, and the mechanism may be closely related to the oxidative damage of mitochondria. Rac1 might be a potential target for radiosensitization in poorly differentiated NPC.

Identifiants

pubmed: 32454130
pii: S0928-0987(20)30167-6
doi: 10.1016/j.ejps.2020.105378
pii:
doi:

Substances chimiques

RAC1 protein, human 0
rac1 GTP-Binding Protein EC 3.6.5.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105378

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Chunmiao Wang (C)

Guangxi medical university, Shuangyong Road No. 22, Nanning 530021, China.

Zhaoquan Li (Z)

Clinical pharmacology discipline, Wuzhou Gongren Honspital, Wuzhou 543000, China.

Zhiyu Pan (Z)

Department of Pharmacy, Guangxi International Zhuang Medicine Hospital, Nanning 530201, China.

Zhengying Su (Z)

Department of Pharmacy, Guangxi International Zhuang Medicine Hospital, Nanning 530201, China.

Wei Tian (W)

Department of Pharmacy, Guangxi International Zhuang Medicine Hospital, Nanning 530201, China.

Fu Lan (F)

Guangxi medical university, Shuangyong Road No. 22, Nanning 530021, China.

Dandan Liang (D)

Guangxi medical university, Shuangyong Road No. 22, Nanning 530021, China.

Junying Li (J)

Guangxi medical university, Shuangyong Road No. 22, Nanning 530021, China.

Danrong Li (D)

Guangxi medical university, Shuangyong Road No. 22, Nanning 530021, China.

Huaxin Hou (H)

Guangxi medical university, Shuangyong Road No. 22, Nanning 530021, China. Electronic address: houhuaxin@stu.gxmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH